Siegfried Holding AG
SFZN
주식 순위
#4106
Siegfried Holding AG, together with its subsidiaries, engages in contract... Siegfried Holding AG, together with its subsidiaries, engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide. It offers drug substances, including exclusive synthesis that manufactures custom APIs. The company also offers an API portfolio, including non-exclusive APIs and pharma-grade substances that focus on anesthetics, pain and addiction treatment applications, and central nervous and respiratory diseases, as well as caffeine for human health and nutrition. In addition, it offers drug products, including steriles, which includes fill and finish in vials, ampoules, cartridges, and pre-filled syringes; ophthalmics, such as sterile ointments, gels, and suspensions and solutions; inhalation products, including capsules in medical devices for inhalation applications; oral solid dosage forms, which includes tablets and capsules; and viral vectors, such as AAV and lentiviruses for gene therapy. Further, the company provides technologies with chemistry capabilities, analytical services, formulation technologies, bridging technologies, containment technology, and cell and gene therapies. The company was founded in 1873 and is headquartered in Zofingen, Switzerland.
주가
$88.34
시가총액
$3.87B
변동 (1일)
1.68%
변동 (1년)
-12.97%
국가
CH
거래 Siegfried Holding AG (SFZN)
카테고리
Healthcare
Siegfried Holding AG (SFZN)의 매출
Oct 2026 기준 매출 TTM: 0
Siegfried Holding AG의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Siegfried Holding AG의 수익 기록 (2002 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2025 | $1.67B | 16.75% |
| 2024 | $1.43B | -5.21% |
| 2023 | $1.51B | 13.69% |
| 2022 | $1.33B | 9.98% |
| 2021 | $1.21B | 28.54% |
| 2020 | $940.74M | 9.18% |
| 2019 | $861.60M | 6.71% |
| 2018 | $807.42M | 4.86% |
| 2017 | $770.00M | 9.19% |
| 2016 | $705.17M | 46.67% |
| 2015 | $480.78M | 51.48% |
| 2014 | $317.39M | -24.47% |
| 2013 | $420.19M | 4.56% |
| 2012 | $401.86M | 15.06% |
| 2011 | $349.27M | 3.82% |
| 2010 | $336.43M | 22.82% |
| 2009 | $273.92M | 1.32% |
| 2008 | $270.33M | -4.00% |
| 2007 | $281.59M | 14.52% |
| 2006 | $245.88M | 1.65% |
| 2005 | $241.89M | -14.43% |
| 2004 | $282.67M | -4.53% |
| 2003 | $296.08M | 2.63% |
| 2002 | $288.49M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
